Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Barbieri

Showing results (291-300 of 305) with videos related to

Pageof 31
Sort By:
Neoplasia (New York, N.Y.)|February 25, 2014
SPOP mutations in prostate cancer across demographically diverse patient cohortsMirjam Blattner, Daniel J Lee, Catherine O'Reilly, et al.
JCO Precision Oncology|July 16, 2024
Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective StudyJohn Nikitas, Kritika Subramanian, Nimrod Barashi Gozal, et al.
European Urology Oncology|June 10, 2025
A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single InstitutionHimanshu Nagar, Marshall A Diven, Brady Rippon, et al.
Nature Communications|January 8, 2024
Distinct mesenchymal cell states mediate prostate cancer progressionHubert Pakula, Mohamed Omar, Ryan Carelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2018
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone SensitivityGunther Boysen, Daniel N Rodrigues, Pasquale Rescigno, et al.
Nature Medicine|August 15, 2017
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4Xiangpeng Dai, Wenjian Gan, Xiaoning Li, et al.
Vaccine|November 29, 2022
Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort studyC Willame, C Dodd, C E Durán, et al.
Nature Genetics|June 2, 2019
Publisher Correction: The long tail of oncogenic drivers in prostate cancerJoshua Armenia, Stephanie A M Wankowicz, David Liu, et al.
Nature Genetics|April 4, 2018
The long tail of oncogenic drivers in prostate cancerJoshua Armenia, Stephanie A M Wankowicz, David Liu, et al.
Cell|April 30, 2013
Punctuated evolution of prostate cancer genomesSylvan C Baca, Davide Prandi, Michael S Lawrence, et al.
Pageof 31

Showing results (291-300 of 305) with videos related to

Sort By:
Pageof 31
Neoplasia (New York, N.Y.)|February 25, 2014
SPOP mutations in prostate cancer across demographically diverse patient cohortsMirjam Blattner, Daniel J Lee, Catherine O'Reilly, et al.
JCO Precision Oncology|July 16, 2024
Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective StudyJohn Nikitas, Kritika Subramanian, Nimrod Barashi Gozal, et al.
European Urology Oncology|June 10, 2025
A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single InstitutionHimanshu Nagar, Marshall A Diven, Brady Rippon, et al.
Nature Communications|January 8, 2024
Distinct mesenchymal cell states mediate prostate cancer progressionHubert Pakula, Mohamed Omar, Ryan Carelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2018
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone SensitivityGunther Boysen, Daniel N Rodrigues, Pasquale Rescigno, et al.
Nature Medicine|August 15, 2017
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4Xiangpeng Dai, Wenjian Gan, Xiaoning Li, et al.
Vaccine|November 29, 2022
Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort studyC Willame, C Dodd, C E Durán, et al.
Nature Genetics|June 2, 2019
Publisher Correction: The long tail of oncogenic drivers in prostate cancerJoshua Armenia, Stephanie A M Wankowicz, David Liu, et al.
Nature Genetics|April 4, 2018
The long tail of oncogenic drivers in prostate cancerJoshua Armenia, Stephanie A M Wankowicz, David Liu, et al.
Cell|April 30, 2013
Punctuated evolution of prostate cancer genomesSylvan C Baca, Davide Prandi, Michael S Lawrence, et al.
Pageof 31